All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Idarubicin dose escalation during consolidation therapy in adult AML patients - phase III ALLG M12 study
Increased doses of daunorubicin, an anthracycline, during induction therapy have been shown to improve remission rates and survival in Acute Myeloid Leukemia (AML) patients.1
In order to further improve the outcomes of AML patients by increased anthracycline dose, Kenneth F. Bradstock from the Westhead Hospital, University of Sydney, and colleagues, on behalf of the Australasian Leukaemia & Lymphoma Group (ALLG), conducted a phase III study (ALLG M12, Australian New Zealand Clinical Trials Registry [ANZCTR] number – 12605000095662) in which standard consolidation was compared to increased idarubicin dose during consolidation therapy after high-dose cytarabine-based induction. The results of the study were published ahead of print in the Journal of Clinical Oncology on 3rd April 2017.2
A total of 293 AML patients (median age = 45 years) in complete remission after induction therapy were randomly assigned to receive two cycles of standard (cytarabine 100 mg/m2 daily for 5 days and etoposide 75 mg/m2 daily for 5 days, n = 146) or intensive (idarubicin 9 mg/m2 daily for either 2 or 3 days, n = 147) consolidation treatment.
The key results of the study were:
- 3-year Leukemia Free Survival (LFS) in patients in the intensive and standard arm; 47% vs 35%, HR = 0.74, P = 0.045
- 3-year Overall Survival (OS) in patients in the intensive and standard arm; 61% vs 50%, HR = 0.75, P = 0.092
- Duration of grade 3–4 neutropenia and thrombocytopenia was significantly longer in the intensive arm than the standard arm
- Grade 3–4 non-hematological toxicities were similar in both the intensive and standard arms
- There was no benefit for intensive consolidation in specific cytogenetics and FLT3 and NPM1 gene mutation subgroups
The authors concluded by stating that “increased dose intensity of idarubicin during consolidation therapy for adult AML results in improved LFS, without increased non-hematologic toxicity”. They further suggested that increased idarubicin intensity should be explored in order to improve outcomes of patients with AML.
Abstract
Purpose
Higher doses of the anthracycline daunorubicin during induction therapy for acute myeloid leukemia (AML) have been shown to improve remission rates and survival. We hypothesized that improvements in outcomes in adult AML may be further achieved by increased anthracycline dose during consolidation therapy.
Patients and Methods
Patients with AML in complete remission after induction therapy were randomly assigned to receive two cycles of consolidation therapy with cytarabine 100 mg/m2 daily for 5 days, etoposide 75 mg/m2 daily for 5 days, and idarubicin 9 mg/m2 daily for either 2 or 3 days (standard and intensive arms, respectively). The primary end point was leukemia-free survival (LFS).
Results
Two hundred ninety-three patients 16 to 60 years of age, excluding those with core binding factor AML and acute promyelocytic leukemia, were randomly assigned to treatment groups (146 to the standard arm and 147 to the intensive arm). Both groups were balanced for age, karyotypic risk, and FLT3–internal tandem duplication and NPM1 gene mutations. One hundred twenty patients in the standard arm (82%) and 95 patients in the intensive arm (65%) completed planned consolidation (P < .001). Durations of severe neutropenia and thrombocytopenia were prolonged in the intensive arm, but there were no differences in serious nonhematological toxicities. With a median follow-up of 5.3 years (range, 0.6 to 9.9 years), there was a statistically significant improvement in LFS in the intensive arm compared with the standard arm (3-year LFS, 47% [95% CI, 40% to 56%] v 35% [95% CI, 28% to 44%]; P = .045). At 5 years, the overall survival rate was 57% in the intensive arm and 47% in the standard arm (P = .092). There was no evidence of selective benefit of intensive consolidation within the cytogenetic or FLT3–internal tandem duplication and NPM1 gene mutation subgroups.
Conclusion
An increased cumulative dose of idarubicin during consolidation therapy for adult AML resulted in improved LFS, without increased nonhematologic toxicity.
References